Nanopharmaceuticals Market Report 2024

This Nanopharmaceuticals market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The nanopharmaceuticals market size has grown rapidly in recent years. It will grow from $80.97 billion in 2023 to $95.21 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The historical growth can be attributed to several factors, including the demand for more effective treatments, growing awareness of nanopharmaceuticals, an increasing demand for targeted therapies, rising incidences of neurodegenerative diseases, and the aging population.

The nanopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $183.89 billion in 2028 at a compound annual growth rate (CAGR) of 17%. The anticipated growth during the forecast period can be attributed to several factors, including the rising prevalence of chronic diseases, increased research and development efforts, growing investments in healthcare, heightened demand for personalized medicine, and the increasing incidence of cancers. Key trends expected during this period include the integration of nanotechnology with other emerging technologies, advancements in nano-enabled drug delivery systems, progress in biotechnology and genomics, the incorporation of AI, machine learning, and computational modeling, and continued technological innovation.

The increasing prevalence of chronic diseases is expected to drive the growth of the nanopharmaceuticals market in the coming years. Chronic diseases, such as cancer, diabetes, heart disease, and asthma, are long-term conditions that typically require ongoing medical attention and management. Factors contributing to the rising prevalence of these diseases include unhealthy diets, lack of physical activity, tobacco use, excessive alcohol consumption, genetic predisposition, and environmental influences. Nanopharmaceuticals are utilized in treating chronic diseases by offering targeted drug delivery, enhanced bioavailability, controlled release, reduced side effects, and advanced combination therapies, all of which improve treatment efficacy and patient outcomes. For example, in April 2022, the National Association of Chronic Disease Directors (NACDD), a US-based non-profit organization, reported that nearly 60% of American adults have at least one chronic disease, and around 40% have multiple chronic conditions (MCC). This prevalence is expected to cost the US economy $2 trillion annually, or $8,600 per person, by 2030. Therefore, the growing incidence of chronic diseases is fueling the expansion of the nanopharmaceuticals market.

Major companies in the nanopharmaceuticals market are increasingly adopting strategic partnerships to enhance communication services for individuals, businesses, and governments. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in April 2024, Nanoform Finland Plc, a Finland-based nanoparticle medicine company, joined forces with CBC Co. Ltd., a Japan-based development-focused trading company, to explore opportunities for Nanoform’s advanced nanomedicine engineering technologies. This collaboration represents a significant milestone in their efforts to utilize cutting-edge nanotechnology to improve medicines for patients globally.

In February 2022, Merck KGaA, a Germany-based company specializing in healthcare, life sciences, and performance materials, acquired Exelead Inc. for $780 million. This acquisition aims to strengthen Merck's capabilities in advanced drug delivery, particularly by integrating Exelead's expertise in lipid nanoparticle technology, which is essential for developing and producing innovative therapies, including mRNA-based treatments. Exelead Inc. is a US-based company that manufactures complex injectable formulations, including lipid nanoparticle (LNP) technology.

Major companies operating in the nanopharmaceuticals market are Selecta Biosciences Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Abvie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Novovax Inc., OSI Pharmaceuticals Inc., Par Pharmaceutial Inc., Samyang Biopharm Corporation.

North America was the largest region in the global nanopharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nanopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nanopharmaceuticals are a category of pharmaceutical drugs that leverage nanotechnology to enhance the delivery, targeting, and effectiveness of therapeutic agents. These drugs are formulated at the nanoscale, typically ranging from 1 to 100 nanometers, and are designed to improve drug solubility, stability, bioavailability, and targeted delivery to specific cells or tissues. Nanopharmaceuticals represent an advanced approach in medicine, offering the potential for more precise, effective, and safer treatments across various diseases.

The primary types of nanopharmaceuticals include liposomes, polymeric micelles, solid lipid nanoparticles, microemulsions, nanoemulsions, and others. Liposomes are small, spherical vesicles composed of phospholipids that can encapsulate drugs, enhancing their delivery to targeted cells or tissues. They help protect the drug from degradation and improve its absorption. Nanopharmaceuticals can be administered through various routes, including oral, injectable, topical, pulmonary, and others. Their applications span multiple therapeutic areas such as oncology, neurology, anti-inflammatory, anti-infective, cardiovascular, and more. These drugs are utilized by several end-users, including hospitals and clinics, specialty pharmacies, research institutions, and others.

The nanopharmaceuticals market research report is one of a series of new reports that provides nanopharmaceuticals market statistics, including nanopharmaceuticals industry global market size, regional shares, competitors with a nanopharmaceuticals market share, detailed nanopharmaceuticals market segments, market trends, and opportunities, and any further data you may need to thrive in the nanopharmaceuticals industry. This nanopharmaceuticals research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nanopharmaceuticals market consists of sales of dendritic nanoparticles, quantum dots, micellar nanoparticles, and gene delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.